Get notified when INNV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Civil Investigative Demand (worsened) — The company recorded a $37.0 million litigation accrual related to the 2021 and 2022 DOJ civil investigative demands, whereas the prior year stated it was unable to estimate possible losses.
Full-year net loss of $2.5M against a loss of $30.3M a year earlier; InnovAge swings to operating income on 15.9% revenue growth, but DOJ accrual and Medicaid cuts loom
Filed September 9, 2026 · Period ending June 30, 2026 · Compared to 10-K Sep 9, 2025 · ~1 min read
Key Changes
-
high
Revenue rose 15.9% to $989.7M, and operating income swung from a loss, driven by higher capitation rates and enrollment.
MD&A verify on EDGAR → -
high
Net loss narrowed, but a litigation expense increase, including a accrual for DOJ civil investigative demands, weighed on results.
MD&A / Notes view on EDGAR → -
high
California paused all new PACE center applications at least two years, and Colorado Medicaid premium rates are expected to decrease retroactively to July 1, 2026.
MD&A verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
Partner
Trade INNV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 11, 2026 · How we verify